Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23053066 | 0.81 | GAA (0.42) | CYP1A2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL16519359 | 0.80 | CYP1A2 (0.53) | CYP1A2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL1001660 | 0.78 | CYP1A2 (0.50) | CYP1A2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL26311965 | 0.78 | GAA (0.52) | CYP1A2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL16268836 | 0.78 | CYP1A2 (0.50) | CYP1A2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL25658525 | 0.78 | CYP1A2 (0.50) | CYP1A2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL8466902 | 0.76 | GAA (0.38) | CYP1A2GAAKDM4EALDH1A1HPGD | |
| SCHEMBL18785383 | 0.76 | GABRA2 (0.49) | GAAKDM4EALDH1A1HPGDPOLB | |
| SCHEMBL1277651 | 0.76 | GABRA2 (0.53) | CYP1A2GAAGABRA2GABRB2 | |
| SCHEMBL20379028 | 0.73 | CYP1A2 (0.45) | CYP1A2GAAKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175804-A1 | NUCLEAR TRANSPORT MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-08-29 | — | — | WO | disclosed |
| US-7329668-B2 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329668-B2 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-12 | — | — | US | disclosed |
| US-7071333-B2 | Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050038054-A1 | Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-17 | — | — | US | disclosed |
| WO-2005011609-A2 | TRIAZOLOPURINE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040204432-A1 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004075846-A2 | PYRAZOLOPURINE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-10 | — | — | WO | disclosed |
| EP-0785937-A1 | 2-(IMIDAZOL-4-YL)CARBAPENEME DERIVATIVES, INTERMEDIATES THEREOF AND USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011932-A1 | 2-(IMIDAZOL-4-YL)CARBAPENEME DERIVATIVES, INTERMEDIATES THEREOF AND USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-25 | — | — | WO | disclosed |
| EP-0605524-A1 | ANTIBACTERIAL, ANTIMYCOPLASMAL COMPOUNDS RELATED TO MUPIROCIN | SMITHKLINE BEECHAM PLC (GB) | 1994-07-13 | — | — | EP | disclosed |
| WO-1993006118-A1 | ANTIBACTERIAL, ANTIMYCOPLASMAL COMPOUNDS RELATED TO MUPIROCIN | SMITHKLINE BEECHAM PLC (GB) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038054-A1 | Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, TYMP, HPRT1 | CYP1A2 172/4885GAA 3407/4885KDM4E 1442/4885 |
| US-20040204432-A1 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, HPRT1, TYMP | CYP1A2 173/4885GAA 3590/4885KDM4E 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.